Genetic Predictors of Lithium Response

Lithium remains a first-line pharmacological treatment of bipolar disorder (BD). However, treatment response is heterogeneous, with several lines of evidence implicating genetic factors. Unfortunately, neither hypothesis-driven approaches nor initial genome-wide association studies (GWAS) were succe...

Full description

Saved in:
Bibliographic Details
Main Author: U. Heilbronner
Format: Article
Language:Russian
Published: Federal State Budget Scientific Institution National Medical Research Center for Psychiatry and Neurology n.a. V.M. Bekhterev Ministry of Health of the Russian Federation 2019-12-01
Series:Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева
Subjects:
Online Access:https://www.bekhterevreview.com/jour/article/view/295
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lithium remains a first-line pharmacological treatment of bipolar disorder (BD). However, treatment response is heterogeneous, with several lines of evidence implicating genetic factors. Unfortunately, neither hypothesis-driven approaches nor initial genome-wide association studies (GWAS) were successful in identifying genetic drivers of response heterogeneity, probably due to low statistical power and different phenotype measurements. Recently, a GWAS of the Consortium of Lithium Genetics (ConLiGen) has identified four single nucleotide polymorphisms (SNPs) mediating response to lithium, located in genes for two long non-coding RNAs. This success was only possible by international collaboration and the use of an established lithium response scale. The findings await further replication.
ISSN:2313-7053
2713-055X